HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

alniditan

structure given in first source
Also Known As:
N-(3,4-dihydro-2H-1-benzopyran-2-yl methyl)-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine dihydrochloride; R 091274; R-091274; R091274
Networked: 10 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Diener, H C: 2 articles (07/2001 - 03/2001)
2. Study Group: 2 articles (07/2001 - 03/2001)
3. Dahlöf, C: 1 article (07/2001)
4. Ferrari, M D: 1 article (07/2001)
5. Mathew, N: 1 article (07/2001)
6. Olesen, J: 1 article (07/2001)
7. Tfelt-Hansen, P: 1 article (07/2001)
8. de Beukelaar, F: 1 article (07/2001)
9. De Beukelaar, F: 1 article (03/2001)
10. Louis, P: 1 article (03/2001)

Related Diseases

1. Migraine Disorders (Migraine)
2. Headache (Headaches)
11/01/1996 - "Time to onset of relief decreased with increasing alniditan dose, and there was a dose-dependent reduction in headache recurrence rate: 25% of patients receiving 1.4 mg had responded by 15 min and headache recurred within 24 h in only 16% of the patients who initially responded to alniditan 1.4 mg, significantly less than for placebo (p = 0.018). "
11/01/1996 - "At 2 h after injection, headache was absent or mild in 83% and 82% of patients receiving alniditan 1.2 and 1.4 mg respectively compared with 39% for placebo (p < or = 0.002). "
03/01/1999 - "To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement. "
11/01/1996 - "Comparison with published findings suggests that alniditan 1.4 mg sc may have advantages over sumatriptan 6 mg sc in providing complete relief from acute migraine headache, and may be associated with fewer headache recurrences within 24 h. "
07/01/2001 - "The number of subjects who were pain free at 2 h (primary endpoint) was: 22 (14.1%) with placebo, 174 (56.3%) with alniditan 1.4 mg, 87 (61.7%) with alnditan 1.8 mg and 209 (65.9%) with sumatriptan 6 mg. Alniditan 1.4 mg was significantly better (P < 0.001) than placebo and sumatriptan was significantly better (P = 0.015) than alniditan 1.4 mg. The number of responders (reduction of headache severity from moderate or severe headache before treatment to mild or absent at 2 h), was 59 (37.8%) on placebo, 250 (80.9%) on alniditan 1.4 mg, 120 (85.1%) on alniditan 1.8 mg, and 276 (87.1%) on sumatriptan. "
3. Glioma (Gliomas)
4. Photophobia (Light Sensitivity)
5. Neurogenic Inflammation

Related Drugs and Biologics

1. Sumatriptan (Imigran)
2. Serotonin (5 Hydroxytryptamine)
3. Dihydroergotamine (Agit)
4. naratriptan
5. indole
6. Nasal Sprays
7. Serotonin 5-HT1 Receptor Agonists
8. 5-HT1D Serotonin Receptor
9. 5-HT1B Serotonin Receptor
10. Butyric Acid (Butanoic Acid)

Related Therapies and Procedures

1. Subcutaneous Injections
2. Electrodes (Electrode)